세계의 반려동물 의약품 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2025-2033년)

Global Companion Animal Pharmaceuticals Market size is anticipated to grow from USD 18.81 Billion in 2024 to USD 30.35 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 5.46% during the forecast period of 2026 to 2033.

The companion animal pharmaceuticals market is poised for significant growth as pet ownership continues to rise globally, leading to an increased focus on the health and well-being of pets. As pet owners increasingly view their animals as family members, the demand for veterinary medicines, including vaccines, anti-parasitics, and pain management solutions, is surging. This trend is further fueled by the growing awareness of preventive healthcare and the importance of regular veterinary check-ups. As the market evolves, pharmaceutical companies are likely to invest in research and development to create innovative treatments that address the specific health needs of companion animals, ensuring a robust trajectory for future growth.

Moreover, advancements in veterinary medicine and technology are enhancing the capabilities of companion animal pharmaceuticals. The development of targeted therapies and biologics is revolutionizing the treatment landscape, offering more effective and safer options for managing various health conditions in pets. Additionally, the rise of telemedicine in veterinary care is facilitating access to pharmaceuticals, allowing pet owners to consult with veterinarians remotely and obtain necessary medications more conveniently. As the market continues to adapt to these technological advancements, the focus on innovation and accessibility will drive growth in the companion animal pharmaceuticals sector.

Furthermore, the increasing emphasis on pet wellness and preventive care is influencing the companion animal pharmaceuticals market, as pet owners seek products that promote overall health and longevity. Nutraceuticals and supplements designed to support joint health, skin and coat condition, and digestive health are gaining popularity among consumers. As the market evolves, the integration of pharmaceuticals with wellness products will create new opportunities for manufacturers to cater to the holistic health needs of companion animals. With a focus on innovation, accessibility, and consumer education, the future of the companion animal pharmaceuticals market looks promising, paving the way for enhanced pet care solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Animal Type

• Dogs
• Cats
• Horses

By Route of Administration

• Oral
• Injectable
• Topical

By Product

• Drugs
• Vaccines
• Medicated Feed Additives

By Drug Class

• Antibiotics
• Anti-inflammatory
• Heart Worm Drugs
• Parasiticides
• Nutritional Drugs
• Behavioral Drugs
• Vaccines
• Others

By Distribution Channel

• Veterinary Hospitals
• Clinics
• COMPANIES PROFILED
• Boehringer Ingelheim International GmbH
• Ceva
• Balchem Corp.
• Chanelle Pharma
• Dechra Pharmaceuticals Limited
• Elanco or its affiliates
• ECO - Animal Health Ltd.
• Enovis Corporation
• Invetx
• Merck & Co. Inc.
• MP AGRO CO.
• LTD.
• Neogen Corporation
• Norbrook
• Orion Corporation
• Sumitomo Corporation
• The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. COMPANION ANIMAL PHARMACEUTICALS – INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Form
  • 3.7.2 Market Attractiveness Analysis By Indication
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Product
  • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET ANALYSIS BY FORM

• 5.1. Overview By Form
• 5.2. Historical and Forecast Data Analysis By Form
• 5.3. Horses Historic and Forecast Sales By Regions
• 5.4. Cats Historic and Forecast Sales By Regions
• 5.5. Dogs Historic and Forecast Sales By Regions
• 5.6. Companion Animals Historic and Forecast Sales By Regions

6. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET ANALYSIS BY INDICATION

• 6.1. Overview By Indication
• 6.2. Historical and Forecast Data Analysis By Indication
• 6.3. Dermatologic Diseases Historic and Forecast Sales By Regions
• 6.4. Infectious Diseases Historic and Forecast Sales By Regions
• 6.5. Behavioral Diseases Historic and Forecast Sales By Regions
• 6.6. Orthopedic Diseases Historic and Forecast Sales By Regions

7. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Overview By Distribution Channel
• 7.2. Historical and Forecast Data Analysis By Distribution Channel
• 7.3. Hospital Pharmacy Historic and Forecast Sales By Regions
• 7.4. E-Commerce Historic and Forecast Sales By Regions
• 7.5. Retail Historic and Forecast Sales By Regions

8. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET ANALYSIS BY PRODUCT

• 8.1. Overview By Product
• 8.2. Historical and Forecast Data Analysis By Product
• 8.3. Vaccine Historic and Forecast Sales By Regions
• 8.4. Biologics Historic and Forecast Sales By Regions

9. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East Africa By Segment Sales Analysis
  • 9.7.3 Middle East Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE COMPANION ANIMAL PHARMACEUTICALS COMPANIES

• 10.1. Companion Animal Pharmaceuticals Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF COMPANION ANIMAL PHARMACEUTICALS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Merck Animal Health
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Zoetis Inc.
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Dechra Pharmaceuticals PLC
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Elanco Animal Health
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Neogen Corporation
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Boehringer Ingelheim Animal Health
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Aratana Therapeutics
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Bayer Animal Health
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Norbrook Laboratories
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Virbac
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Kindred Biosciences
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. Ceva Sante Animale
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies